Pfizer Inc. (NYSE: PFE) Is About to Trade Ex-dividend

Pfizer Inc. (NYSE: PFE) has announced that it will soon trade ex-dividend. This announcement signals the company’s investors to make their moves. The ex-dividend date refers to the day before a company decides which of its shareholders will get a dividend. Pfizer’s dividend will be $0.40 per share. Pfizer announces the real-world benefits of IBRANCE […]

Pfizer Inc. (NYSE: PFE) Finds That Paxlovid Cannot Prevent COVID-19 Infection

Pfizer Inc. (NYSE: PFE) has found that its Paxlovid pill might not effectively prevent COVID-19 in people who have come in contact with infected individuals. Paxlovid is an oral drug which the Food and Drug Administration (FDA) approved for the treatment of COVID-19. In the study, the company gave the pill to people for five […]

Zacks Analyst Look At The Future of Pfizer Inc. (NYSE: PFE)

Zacks Analyst has placed Pfizer Inc. (NYSE: PFE) on the list of the most searched stock. This news is unsurprising as the company has performed well in recent months. Now investors wonder what the future is for the company. Zacks Analyst gives investors an idea of what to expect. For example, analysts believe that the […]

Britain Boosts Access to Pfizer Inc (NYSE: PFE) COVID Antiviral Drug

Britain wishes to protect its citizens by increasing access to the Pfizer Inc (NYSE: PFE) oral antiviral COVID-19 treatment. Its move will benefit thousands, provided it will successfully add the oral antiviral to a trial to establish the best way to use the drug. Britain has done a remarkable job vaccinating a large percentage of […]

Pfizer Inc. (NYSE: PFE) Has Produced 6 Million Paxlovid Pills

Pfizer Inc. (NYSE: PFE) announced that it surpassed the target that Albert Bourla, its CEO, set and developed 6 million Paxlovid pills. Paxlovid is an oral pill that treats COVID-19. The company also stated that it had sent these pills to 26 counties. It hopes to create about 120 million pills in 2022. Meanwhile, the […]

Pfizer Inc. (NYSE: PFE) Gets Breakthrough Therapy Designation For RSVpreF

The U.S Food and Drug Administration (FDA) has given Pfizer Inc. (NYSE: PFE) the Breakthrough Designation for RSVpreF, its vaccine for respiratory syncytial virus (RSV). The vaccine is for people aged 60 and above. This move comes after Pfizer conducted a Phase IIa clinical trial that looked into the efficacy, immunogenicity, and safety of the […]

Pfizer Inc. (NYSE: PFE) Recalls Accuretic For Nitrosamine Contamination

Pfizer Inc. (NYSE: PFE) has recalled some lots of Accuretic, a hypertension drug. The company is also recalling two cheaper versions of Accuretic. This move is due to nitrosamine, which is carcinogenic, in the medication. While Pfizer has said that patients who take the drug are not at immediate risk of developing cancer, taking nitrosamines […]

Pfizer Inc. (NYSE: PFE) Study Shows The Company Gives Equitable Pay to Workers

Pfizer Inc. (NYSE: PFE) has stated for the third time that a compensation expert has recognized that the company offers equitable pay to workers. This announcement came after a study on gender-based pay worldwide and for U.S minorities. It used bonuses, merit increases, and base pay to assess payment equity. The study also adjusted for […]

Pfizer Inc. (NYSE: PFE) Drug, Paxlovid, Becomes Readily Available As Omicron Subsides

The Pfizer Inc. (NYSE: PFE) drug, Paxlovid, is becoming more available as the number of omicron infections dwindles. The drug which the Food and Drug Administration (FDA) approved had been difficult to obtain during the spike, leaving a gap for patients with mild cases of the disease. Meanwhile, Pfizer and BioNTech SE’s (NASDAQ: BNTX) omicron […]

Pfizer Inc. (NYSE: PFE) and Other Biotechnology Service Companies Could Reach a Market Capitalization of $151.10 Billion

Pfizer Inc. (NYSE: PFE) is among the companies in the biotechnology services market that analysts expect to grow in 2022. These companies could amass a market cap of $151.10 billion in 2022. Other significant players in this category include Precision for Medicine, BioAlps, Novo Nordisk, Pfizer, Fisher BioService, and Novartis. The FDA and CDC are […]

Pfizer Inc. (NYSE: PFE) Records a Gain of 42.2% in the Last Six Months

Pfizer Inc. (NYSE: PFE) has gained 42.2% in the past six months. This is because of some of its breakthrough projects, including receiving approval from the Food and Drug Administration (FDA) for its COVID-19 booster. The company also received approval for vaccines for children between 12 to 15. Moreover, Pfizer received Breakthrough Therapy Designation (“BTD”) […]

Pfizer Inks A Research Collaboration with Beam Therapeutics

Pfizer (PFE) has inked four-year research collaboration agreement with biotechnology company Beam Therapeutics (BEAM). The two are joining forces to advance the development of novel in-vivo base editing programs. PFE shares rose 0.93% to close at $56.24 on January 10. Pfizer is a company that develops, manufactures, and distributes healthcare products, including medicine and vaccines. […]

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) Are Partnering on a Shingles mRNA Vaccine

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have begun a new partnership to commercialize, develop, and research an mRNA vaccine for Shingles.  The disease, a form of the varicella-zoster virus, affects about 1 in 3 Americans. It affects people with cancer and those above the age of 50. It causes painful, disfiguring patches. […]

Pfizer Inc (NYSE: PFE), Moderna Inc (NASDAQ: MRNA) and Johnson & Johnson (NYSE: JNJ) Booster Jabs For All Who Are 18+, Six Months After Receiving The Second Dose

Pfizer Inc (NYSE: PFE), Moderna Inc (NASDAQ: MRNA) and Johnson & Johnson (NYSE: JNJ) booster dose of the vaccine against coronavirus is administered. Those above 18 can select which booster dose they want Those over 18-years of age can select which of the three dosages they wish to be administered. Pfizer and Moderna booster shot […]

AbbVie Inc (NYSE: ABBV) and Aurobindo Pharma Ltd Could Benefit From a Growth in the Female Infertility Drugs Market

Technavio has reported that Abbie Inc (NYSE: ABBV) and Aurobindo Pharma Ltd could benefit the female infertility drug market growth. Technavio expects North America to play a vital role in increasing the market. Calculations show that the region could account for 35% growth. Despite this, Europe and Asia will experience faster growth. Between 2020 and […]